Uno Studio di Fase 1 su PRT12396 in Partecipanti con Neoplasie Mieloproliferative Selezionate
Studio di Fase 1, in Aperto, Multicentrico, sulla Sicurezza e l'Efficacia di PRT12396 in Partecipanti con Policitemia Vera e Mielofibrosi
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.
The study is conducted in two parts:
Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).
Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.
Approximately up to 100 participants are planned for enrollment across both parts of the study.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Study Contact (Please Do Not Disclose Personal Information)
- Numero di telefono: See Email
- Email: clinicaltrials@preludetx.com
Luoghi di studio
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Reclutamento
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Reclutamento
- Monash Health, Monash Medical Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamento
- One Clinical Research
-
-
-
-
-
Nice, Francia, 06200
- Reclutamento
- Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
-
Paris, Francia, 75010
- Reclutamento
- Saint-Louis Hospital
-
Toulouse, Francia, 31059
- Reclutamento
- Oncopole Claudius Regaud
-
-
-
-
-
Florence, Italia, 50134
- Reclutamento
- Azienda Ospedaliero Universitaria Careggi
-
-
-
-
-
Barcelona, Spagna, 08036
- Reclutamento
- Hospital Clinic de Barcelona
-
Madrid, Spagna, 28034
- Reclutamento
- Hospital Universitario Ramon y Cajal
-
Madrid, Spagna, 28041
- Reclutamento
- Hospital Universitario 12 de Octubre
-
Valencia, Spagna, 46010
- Reclutamento
- Hospital Clínico Universitario de Valencia
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- UCLA Ronald Reagan Medical Center
-
Sacramento, California, Stati Uniti, 95817
- Reclutamento
- University of California, Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80218
- Reclutamento
- Colorado Blood Cancer Institute
-
-
Florida
-
Coral Springs, Florida, Stati Uniti, 33065
- Reclutamento
- BRCR Global - Coral Springs
-
Miami, Florida, Stati Uniti, 33136
- Reclutamento
- Sylvester Comprehensive Cancer Center
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Moffitt Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49546
- Reclutamento
- START Midwest, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19107
- Reclutamento
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tristar BMT
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology, PLLC - Investigational Drug Services
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- The University of Texas, MD Anderson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
- Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
- Documented presence of a JAK2 V617 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimate life expectancy of ≥12 weeks per investigator assessment.
- Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
- Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Exclusion Criteria:
- History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
- Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
- Active or uncontrolled infection requiring systemic therapy or hospitalization.
- Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
- Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
- Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
- Pregnancy or breastfeeding
- Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
- Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
- Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
- Participation in another interventional clinical study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: PRT12396: MF
Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
|
Sperimentale: PRT12396: PV
Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT12396
Lasso di tempo: Through cycle 1 (4 weeks)
|
Incidence of dose limiting toxicities, defined according to protocol-specified criteria |
Through cycle 1 (4 weeks)
|
|
Incidence and severity of Adverse events
Lasso di tempo: Through study completion, an average of 2 years
|
Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0 |
Through study completion, an average of 2 years
|
|
Adverse Events Leading to Dose Modifications or Discontinuation
Lasso di tempo: Through study completion, an average of 2 years
|
Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities |
Through study completion, an average of 2 years
|
|
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Lasso di tempo: Through study completion, an average of 2 years
|
Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data |
Through study completion, an average of 2 years
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hematologic Response Rate (PV)
Lasso di tempo: Through study completion, an average of 2 years
|
Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator |
Through study completion, an average of 2 years
|
|
Duration of Hematologic Response (PV)
Lasso di tempo: Through study completion, an average of 2 years
|
Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first |
Through study completion, an average of 2 years
|
|
Hematocrit Control Without Phlebotomy Requirements (PV)
Lasso di tempo: Through study completion, an average of 2 years
|
Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy |
Through study completion, an average of 2 years
|
|
Spleen Response (MF)
Lasso di tempo: Through study completion, an average of 2 years
|
Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length |
Through study completion, an average of 2 years
|
|
Change from Baseline in Hemoglobin (MF)
Lasso di tempo: Through study completion, an average of 2 years
|
Change from baseline in hemoglobin levels in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Platelet Count (MF)
Lasso di tempo: Through study completion, an average of 2 years
|
Change from baseline in platelet count in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Absolute Neutrophil Count (MF)
Lasso di tempo: Through study completion, an average of 2 years
|
Change from baseline in absolute neutrophil count in MF participants |
Through study completion, an average of 2 years
|
|
Transfusion Independence (MF)
Lasso di tempo: Through study completion, an average of 2 years
|
Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria |
Through study completion, an average of 2 years
|
|
Maximum Observed Plasma Concentration (Cmax)
Lasso di tempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Maximum observed plasma concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Time To Maximum Concentration (Tmax)
Lasso di tempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Time to maximum concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Area under the plasma concentration versus time curve (AUC)
Lasso di tempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Area under the plasma concentration-time curve will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Terminal Elimination Half-life (T1/2)
Lasso di tempo: Cycle 1 Day 1
|
Terminal elimination half-life will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Steady State Trough Concentrations
Lasso di tempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Steady state trough concentrations will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Clearance
Lasso di tempo: Cycle 1 Day 1
|
Clearance will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Accumulation
Lasso di tempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Accumulation will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Lasso di tempo: Through study completion, an average of 2 years
|
Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity. |
Through study completion, an average of 2 years
|
|
Patient Global Impression of Change (PGI-C)
Lasso di tempo: Through study completion, an average of 2 years
|
Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms. |
Through study completion, an average of 2 years
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- PRT12396-01
- 2026-525484-40-00 (Ctis)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .